

Docket No.: PH114205.2402/KMZ215101.02402
Customer No. 27160

PATENT/OFFICIAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

William G. KERR

Serial No. 09/955,174

Filed: September 19, 2001

For: CONTROL OF NK CELL FUNCTION AND SURVIVAL BY MODULATION OF SHIP ACTIVITY

:
:
:
:
:
: Group Art Unit: 1614
:
: Examiner: Unassigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents and Trademarks
Washington, D. C. 20231

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

AUTHORIZATION

This Information Disclosure Statement is being filed before receipt of the first Office Action. No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to Deposit Account No. 50-1710.

Respectfully submitted,

KATTEN MICHIN-ZAVIS

Gianna Julian Arnold
Registration No. 36,358

525 West Monroe Street, Suite 1600
Chicago, IL 60661-3693
Facsimile: (312) 902-1061

Date: 5/13/02

DC:4122404V1-114205.2402/15101.02402

RECEIVED
MAY 16 2002
TECH CENTER 1600/2900
#8 / R.T.
6/10
I.D.S.

RECEIVED

MAY 16 2002


TECH CENTER 1600/2900

<p>LIST OF ART CITED BY APPLICANT</p> <p>(PTO-1449)</p> <p>OIPF JC177 MAY 13 2002 PATENT & TRADEMARK OFFICE</p>				<p>ATTY. DOCKET NO.</p> <p>Old: 114205.2402</p> <p>New: 215101.02402</p>		<p>SERIAL NO.</p> <p>09/955,174</p>	
				<p>APPLICANT</p> <p>William G.KERR.</p>			
				<p>FILING DATE</p> <p>September 19, 2001</p>		<p>GROUP</p> <p>1614</p>	
<p align="center">U.S. PATENT DOCUMENTS</p>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	6,090,621	18 Jul 2000	Kavanaugh et al.				
	4,603,112	29 Jul 1986	Paoletti et al.				
	4,769,330	6 Sep 1988	Paoletti et al.				
	5,017,487	21 May 1991	Stunnenberg et al.				
	4,777,127	11 Oct 1988	Suni et al.				
	5,166,057	24 Nov 1992	Palese et al.				
<p align="center">FOREIGN PATENT DOCUMENTS</p>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
	WO 97/10252A1	13 Sep 1996	Rohrschneider, L.R.				
	WO 97/12039A2	27 Sep 1996	Krystal, G.				
	WO 89/01973	9 Mar 1989	Panicali, D. et al.				
	GB 2,200,651	14 Sep 1988	Al-Sumidaie, A.M.K.				
	EP 0,345,242	6 Dec 1989	Jacobs, E. et al.				
	WO 91/02805	7 Mar 1991	Chang, S.M.W. et al.				
	EP 0 440,219	7 Aug 1991	Billeter, M.A. et al.				
	WO 92/06693	30 Apr 1992	Taylor, J.D.				
<p align="center">OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</p>							
	Kapeller et al., "Phosphatidylinositol 3-Kinase," Bioessays, 16, 1994: 565-76.						
	Stephens, L.R. et al., "Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: a new intracellular signalling system?" Biochim. BiophysActa; 1179, 1993: 27-75.						
	Hawkins P.T. et al., "Platelet-derived growth factor stimulates synthesis of PtdIns(3,4,5)P ₃ by activating a PtdIns(4,5)P ₂ 3-OH kinase," Nature; 358, 1992: 157-910.						
	Klippel A. et al., "Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways," Molecular and Cellular Biology, vol. 16, no. 8, 1996: 4117-27.						
	Helgason, C.D. et al., "Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span," Genes & Dev., vol. 12, no. 11, 1998: 1610-20.						
	Huber, M. et al., "The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation," Proc. Natl. Acad. Sci. U.S.A., vol. 95, no. 19, 1998: 11330-35.						
	Liu, Q. et al., "SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation any myeloid cell-survival," Genes & Dev., vol. 13, no. 7, 1999: 789-91						
	Liu, Q. et al., "The inositol polyphosphate 5-phosphatase SHIP is a crucial negative regulator of B cell antigen receptor signalling," J. Exp. Med., vol. 188, no. 7, 1998: 1333-42.						

RECEIVED
MAY 16 2002

TECH CENTER 1600/2900

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Jefferson, A.B. et al., "Properties of type II inositol polyphosphate 5-phosphatase," J. Biol. Chem. vol. 270, no. 16, 1995: 9370-77.
	Wang, C.Y. et al., "pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse," PNAS, vol. 84, 1987: 7851.
	Jolly, D., "Viral vector systems for gene therapy," Cancer Gene Therapy, vol. 1, no. 1, 1994: 51-64.
	Evans, D.J. et al., "An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies," Nature, vol. 339, 1989: 385-88.
	Sabin, A.B. et al., "History of Sabin attenuated poliovirus oral live vaccine strains," J. of Biol. Standardization, vol. 1, 1973: 115-18.
	Fisher-Hoch, S.P. et al., "Protection of rhesus monkeys from fatal Lassa fever by vaccination with recombinant vaccinia virus containing the Lassa virus glycoprotein gene," PNAS, vol. 86, 1989: 317-21.
	Moss, B. et al., "Vaccinia virus expression vectors," Ann. N.Y. Acad. Sci, vol. 569, 1989: 86-103.
	Flexner, C. et al., "Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2," Vaccine, vol. 8, 1990: 17-21.
	Mulligan, R.C. et al., "Synthesis of rabbit β -globin in cultured monkey kidney cells following infection with a SV40 β -globin recombinant genome," Nature, vol. 277, 1979: 108-114.
	Luytjes, W. et al., "Amplification, expression, and packaging of a foreign gene by influenza virus," Cell, vol. 59, 1989: 1107-13.
	McMichael, A.J. et al., "Cytotoxic T-cell immunity to influenza," N. Eng. J. Med., vol. 309, no. 1, 1983: 13-17.
	Yap, K.L. et al., "Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus," Nature, vol. 273, 1978: 238-39.
	Berkner, K.L., "Development of adenovirus vectors for the expression of heterologous genes," BioTechniques, vol. 6, no. 7, 1988: 616-27.
	Rosenfeld, M.A. et al., "Adenovirus-mediated transfer of a recombinant α 1-antitrypsin gene to the lung epithelium in vivo," Science, vol. 252, 1991: 431-34.
	Kolls, J. et al., "Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer," PNAS, vol. 91, 1994: 215-19.
	Kass-Eisler, A. et al., "Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo," PNAS, 90, 1993:11498-502.
	Guzman, R.J. et al., "Efficient and selective adenovirus-mediated gene transfer into vascular neointima," Circulation, vol. 88, no. 6, 1993:2838-48.
	Guzman, R.J. et al., "Efficient gene transfer into myocardium by direct injection of adenovirus vectors," Cir. Res. vol. 73, no. 6, 1993: 1202-07.
	Zabner, J. et al., "Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis," Cell, vol. 75, 1993: 207-16.
	Li, Q. et al., "Assessment of recombinant adenoviral vectors for hepatic gene therapy," Hum. Gene. Ther., vol. 4, 1993: 403-09.
	Caillaud, C. et al., "Adenoviral vector as a gene delivery system into cultured rat neuronal and glial cells," Eur. J. Neurosci., vol. 5, 1993: 1287-91.
	Vincent, N. et al., "Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene," Nat. Genet., vol. 5, 1993: 130-34.
	Jaffe, H.A. et al., "Adenovirus-mediated in vivo gene transfer and expression in normal rat liver," Nat. Genet., Vol. 1, 1992: 372-78.
	Levero, M. et al., "Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo," Gene, vol. 101, 1991: 195-202.
	Samulski, R.J. et al., "Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression," J. Vir. vol. 63, No. 9, 1989: 3822-3828.
	Mendelson, E. et al., "Expression and rescue of a nonselected marker from an integrated AAV vector," Virol., Vol. 166, 1988: 154-65.



TECH CENTER 1600/2900

RECEIVED
MAY 16 2002

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Kit, S., "Recombinant-derived modified-live herpesvirus vaccines;" Immunobiology of Proteins and Peptides V Vaccines: Mechanisms, Design, and Applications, Atassi, M.Z., Ed. Plenum Press, New York, 215, 1989: 219-36.
	Poznansky, M. et al., "Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector;" J. Virol., vol. 65, no. 1, 1991: 532-36.
	Munroe, S.S. et al., "Subgenomic RNA sequence of human astrovirus supports classification of astroviridae as a new family;" J. Vir. Vol. 67, no. 6, 1993: 3611-14.
	Overbaugh, J. et al., "Molecular cloning of a feline leukemia virus that induces fatal immunodeficiency disease in cats;" Science, vol. 239, 1988: 906-10.
	Bender, M.A. et al., "Description and Targeted deletion of 5' hypersensitive site 5 and 6 of the mouse β -globin locus control region;" Blood, 92, 1998:4394-403.
	Lanier, L.L., "NK cell receptors;" Annual Review of Immunology, vol. 16, 1998: 359-93.
	Yokoyama, W.M., "Natural killer cell receptors;" Current Opinion in Immunology, vol. 10, no. 3, 1998: 298-305.
	Koh, C. et al., "Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo;" Blood, vol. 97, no. 10, 2001: 3132-37.
	Ruggeri, L., "Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation;" Blood, vol. 94, no. 1, 1999: 333-39.
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
DC: #4122404v1-114205.2402/15101.02402